Recent discoveries of influenza A drug target sites to combat virus replication.
Sequence variations in the binding sites of influenza A proteins are known to limit the effectiveness of current antiviral drugs. Clinically, this leads to increased rates of virus transmission and pathogenicity. Potential influenza A inhibitors are continually being discovered as a result of high-throughput cell based screening studies, whereas the application of computational tools to aid drug discovery has further increased the number of predicted inhibitors reported. This review brings together the aspects that relate to the identification of influenza A drug target sites and the findings from recent antiviral drug discovery strategies.
School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield, AL10 9AB, U.K. h.patel28@herts.ac.uk.
Hershna
H
Patel
School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield, AL10 9AB, U.K.
Andreas
A
Kukol
D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D055808:Drug Discovery; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects*; D007251:Influenza, Human / Q000188:drug therapy*; D058990:Molecular Targeted Therapy; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents
antiviral discovery; influenza A; inhibitors; resistance; viral proteins